Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and
durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first
line of after failure to first line systemic or liver directed therapy.